

Annual Shareholders' Meeting of SCHOTT Pharma AG & Co. KGaA
on 4th February 2025

Proposal by the personally liable partner on appropriation of the net retained profit

The personally liable partner proposes utilizing the net retained profit of € 67,346,528.25 from the annual financial statements of SCHOTT Pharma AG & Co. KGaA as of 30th September 2024, as follows:

Distribution of a dividend of € 0.16 for each share entitled to a dividend	€ 24,098,338.56
Net profit brought forward	€ 43,248,189.69
Net retained profit	€ 67,346,528.25

Mainz, December 2024

The personally liable partner
SCHOTT Pharma Management AG
The Executive Board



Andreas Reisse



Dr. Almuth Steinkühler